Roche in Switzerland Innovation is our home

Transcription

1 Roche in Switzerland Innovation is our home

2 Roche s sites in Switzerland in context Roche was founded by Fritz Hoffmann-La Roche on 1 October He was one of the first people to recognise that major progress in combatting disease could be achieved by producing standardised medicines industrially. From the very beginning, the visionary entrepreneur geared his company to innovation and an international presence. Today, this multinational presence allows us to offer our healthcare solutions all over the world and meet each region s specific needs. Roche currently employs around 80,000 people worldwide and markets products in over 150 countries. Roche is one of the world s leading healthcare companies with its two strong core businesses of diagnostics and pharmaceuticals. F. Hoffmann-La Roche Ltd Basel Kaiseraugst Roche Pharma (Switzerland) Ltd, Reinach, Canton of Basel-Land Roche Diagnostics International Ltd & Roche Diagnostics (Switzerland) Ltd, Rotkreuz Roche Glycart Ltd, Schlieren About 8,800 people work at Group headquarters in Basel and Kaiseraugst. Global functions and strategic centres for the entire value creation chain, comprising research, development, production and marketing, are based here. Basel is the centre of Roche s metabolism and central nervous system research activities, while among other things, Kaiseraugst is home to Roche s biggest and most modern packing and logistics centre, which ships 120 million packages of medicine each year to customers in 130 countries. About 160 people work in Reinach. Besides marketing and distributing medicines, the site is responsible for coordinating clinical trials in Switzerland, obtaining marketing approval for products in Switzerland and securing reimbursable status for medicines from Swiss health insurance funds. Roche Diagnostics International Ltd in Rotkreuz, Canton of Zug, is one of the world s leading suppliers of diagnostic system solutions. It was founded in 1969 and currently employs over 1,700 people from some 50 nations. All the key functions for the diagnostics business are based at the site. Rotkreuz, which has over 170 staff, is also home to the Swiss sales, marketing and service organisation for diagnostic system solutions, reagents/test strips and IT and workflow services. Roche Glycart AG was established in the year 2000 as a spin-off of the Swiss Federal Institute of Technology (ETH) in Zurich and has been part of the Roche Group since This biotechnology company has a unique technology that is designed to improve the therapeutic effect of antibodies, particularly in oncology. 2 3

3 Editorial Roche specialises in two businesses, pharmaceuticals and diagnostics, and is one of the largest private-sector employers in Switzerland. Roche Pharma (Switzerland) Ltd in Reinach is responsible for clinical trials, obtaining marketing approval for products in Switzerland, securing reimbursable status for medicines from Swiss health insurance funds as well as marketing and distributing Roche s pharmaceutical products in Switzerland. Switzerland has always been our home and will remain so, because it offers an outstanding place to do business. The country boasts high legal certainty, good universities and a plentiful supply of highly skilled employees. As a place to conduct research, however, Switzerland faces growing international competition, especially from Asia. This makes it all the more important for Switzerland to remain open to new developments. A signal must be sent out that Switzerland is reliant on innovative industries and will support them accordingly. Such signals are especially important for the local business in such areas as clinical trials or approval of new medicines and new applications for existing medicines. This brochure deliberately focuses on the research and development of innovative cancer treatments because Roche is the market leader in oncology by a substantial margin. However, as the world s largest biotech company, we not only develop cancer medicines, but also novel treatments in virology, inflammatory and metabolic disorders and diseases of the central nervous system. Roche is also the world s biggest supplier of in-vitro diagnostics. Manfred Heinzer, General Manager, Roche Pharma (Switzerland) Ltd 5

4 What motivates us? Contributing to the development of new and innovative medicines and making them available to patients. And expanding our understanding of approved medicines so that we can help to improve patients safety and quality of life. Marjan Schirinzi & Pascale Gasser (Clinical Operations) A strong commitment to Switzerland As a global enterprise that currently operates in 150 countries, our strong Swiss roots are important to us. Our values of integrity, courage and passion underpin the entire Group, and we uphold them throughout the world. Our deep roots in Switzerland are reflected in Roche s investments in research and development (R&D) in the country. The work enables us to offer interesting employment opportunities to highly qualified staff from all over the world. Not only do we have nearly 11,000 direct employees, but a further 30,000 jobs depend on Roche. As a major Swiss exporter, Roche is a significant contributor to the country s prosperity. Each year, we export goods to a value of CHF 20 billion, or 11% of Switzerland s total export volume. Did you know that Roche invests over CHF 5 million per day in R&D in Switzerland alone? is one of the three leading research institutions in Switzerland? employs 3,500 researchers in Switzerland? is responsible for 11% (CHF 20 billion) of Switzerland s total exports? 7

5 Hope for patients As a leading provider of innovative cancer treatments, Roche plays a key role in giving cancer patients the prospect of a cure and/or better quality of life. Every day counts! We re proud to be able to give patients the gift of a longer and better life by developing new medicines and providing rapid access to them. Dr Constanze Kaiser (Medical Manager Oncology) Did you know that the introduction of two medicines for breast cancer and lymphoma has resulted in around 2,000 patients in Switzerland being cured? Roche products give metastatic cancer patients in Switzerland an additional 9,500 months about 790 years of life every year? four out of five diabetics who wear an insulin pump in Switzerland use a Roche product for greater autonomy and lower treatment costs? since the year 2000, Roche has carried out over 100 clinical trials involving some 1,900 patients in Switzerland? 9

6 Hope for patients One man in three and one woman in four will get cancer by the age of 75 New cancer diagnoses: 34,406 a year Deaths from cancer: 16,500 a year One in four people get cancer at some point in their lives. Until the mid-20 th century, a diagnosis of cancer was in most cases tantamount to a death sentence. Today, thanks to new treatment options, two-thirds of patients are still alive five years after their cancer was first identified. Our research and development work has produced a wide range of treatment options for patients with both curable and incurable conditions. Since the launch of a pioneering breast cancer medicine in 2006, for example, around 1,000 women in Switzerland with this form of cancer have been cured. Roche also offers an innovative treatment option for patients suffering from an aggressive form of non-hodgkin s lymphoma (DLBCL), a malignant disease of the lymphatic system. The lives of some 1,000 DLBCL patients in Switzerland have been saved since this medicine was launched in In incurable patients, modern treatments can slow disease progression and keep symptoms such as pain under control. If a cancer cannot be cured, patients treatment should at least enable them to maintain their quality of life for as long as possible. For example, an extended therapy the first significant progress after 15 years of treating the disease has brought fresh hope to ovarian cancer patients, who can continue to participate in community life in spite of their condition. Holding on to their independence, keeping on working, sharing in the birth of a grandchild or spending a holiday with their family are important experiences which an appropriate treatment can make possible. Source: Association of Swiss Cancer Registries statistics 10 11

7 Innovation means progress Without research there is no innovation and no medical progress. We respond to medical questions with innovation that stems from outstanding scientific achievements. Our highly differentiated products are adapted as best possible to the needs of patients and improve the quality, safety and cost-efficiency of healthcare provision. The regulatory authorities often fast-track the approval of our highly innovative products. The work I do helps to ensure that medical advances reach our patients faster. Daniela Napoli (Drug Regulatory Affairs & Quality Assurance) Did you know that Roche has seven cancer medicines that improve patients chance of survival? Roche s oncology pipeline contains 42 new active ingredients? Roche is the largest supplier of medicines to hospitals in the Swiss domestic market? it takes 8 to 12 years to develop a new active ingredient? (Source: Interpharma, Swiss Pharmaceutical Market, 2011) out of 10,000 substances in the lab, only one makes it to the market? (Source: Interpharma, Swiss Pharmaceutical Market, 2011) it takes an investment of CHF 1 billion, 7 million hours of work and 6,587 experiments by 423 researchers to produce one innovative new medicine? 13

8 Innovation means progress Roche s activities revolve around the discovery and development of novel diagnostic tools and medicines. This creates significant benefits for physicians and patients alike in the prevention, early detection, diagnosis, treatment and monitoring of diseases. Developing innovative treatment options is becoming ever more challenging. Only one molecule in around 10,000 finishes the long and risky road to approval. Bringing a new medicine to market requires eight to twelve years of research and development, primarily CHF investments hours of work experiments 423 researchers 1 medicine as a result of stricter requirements for trials, which make studies longer and therefore costlier. Consequently, half of a new medicine s lifetime on patent has passed before it even becomes available to patients, which leaves less time to build the capital to finance ongoing R&D investments in new molecules. One measure of the innovative power of a new treatment is the fast-track approval process applied to potentially ground-breaking medicines in order to get new therapy options to patients as quickly as possible. In the past four years, eight innovative Roche products and indications have been fast-tracked for approval. This is equivalent to about one-quarter of all medicines reviewed in this way and testimony Roche s strong innovative capacity. Patients can only benefit from novel therapy options if the products are available. Consequently, we work with international and local partners to improve medical care. For example, we are committed to health education programmes, better preventive healthcare services and better access to medicines. We support projects where we can apply our core competencies and expertise to contribute to finding more sustainable solutions

9 Personalised healthcare In focus At Roche, personalised healthcare means being able to offer the right medicine to the right patient at the right time. Did you know that only about 50% of patients benefit from treatment with conventional, non-personalised medicines? Every patient has the right to the best possible treatment of his or her illness, and I work towards this goal every day. Dr Carsten Hofstetter (Personalised Healthcare Manager) Roche s launch of a skin cancer medicine was the first time it successfully brought a personalised healthcare product and companion diagnostic test to market at the same time? over 2,500 patients are treated with Roche personalised medicines in Switzerland each year, thereby benefitting from customised treatment? Roche Diagnostics and Roche Pharmaceuticals are collaborating on a total of 200 personalised healthcare projects? 17

10 Personalised healthcare in focus On average, out of ten patients undergoing the same treatment, only about half benefit. The rest experience no effect or even suffer adverse effects. The nonselective approach of applying the same treatment to every patient is no longer an adequate response to today s needs. "Personalised healthcare", by contrast, offers specific therapies that are tailormade for defined patient groups. In personalised healthcare (PHC), Roche is pursuing differentiated, targeted approaches to treatment for specific patient groups. The medical advance represented by personalised healthcare creates clear added value for patients in terms of treatment and improved quality of life. But other stakeholders benefit as well: Doctors can reach decisions more easily and better predict the outcome of treatment. The institutions that bear the cost of healthcare see more efficient use of resources and a potential reduction in additional treatment and accompanying costs due to unwanted side effects. Professional bodies have a better foundation for developing treatment guidelines. In my view, personalised healthcare will be the only way to achieve optimal resource management. For us insurers, personalised healthcare is extremely important because the non-selective approach of making medicines or technologies available to patients on an indiscriminate basis, so to speak, will be unaffordable in the future. We now have first-class economic analyses that show that diagnosis-based, optimised therapies, such as treatments for hepatitis C or breast and colon cancer, are more economical, particularly from a healthcare Patient groups with the same clinical picture economics perspective, than traditional strategies. (Prof. Thomas Szucs, Board Chairman, Helsana Group, Zurich, Switzerland) Targeted treatment 18 19

11 Cutting costs with effective, well-tolerated medicines Innovative medicines normally cost more than existing therapy options. However, quicker and more effective treatment of diseases can yield savings in overall healthcare costs. Our innovative and targeted therapies help patients get better while simultaneously using resources more efficiently that s something I m proud of. Oliver Aben (Director Finance & Business Partnering) Did you know that in addition to around CHF 60 billion in direct healthcare costs (2009 figure), illness costs society at least as much again (an estimated CHF 74 billion) in indirect costs due to missed work and the cost of caregiving? (Source: Interpharma, Polynomics, 2011) the indirect costs of cancer (60% or CHF 4.6 billion) are proportionately even higher than the direct costs (40% or CHF 3.1 billion)? (Source: Interpharma, Polynomics, 2011) in the next ten years, innovative medicines will generate approximately CHF 17 billion in savings in direct healthcare costs alone? (Source: Swiss Federal Statistical Office, Determinants of Healthcare Costs, 2008) 21

12 Cutting costs with effective, well-tolerated medicines Prescribing the right medicine at the right time and at the proper dosage can relieve the severest consequences of illness. Hospital stays can be shortened or even avoided altogether. Patients can get back to work sooner and experience a lower loss of earnings as a result of Traditional medicines illness. These social and economic benefits extend far beyond the efficacy of the product itself. Innovative medicines help reduce total healthcare costs in the long term by making the treatment of disease quicker and more effective. Innovative medicines Chronic lymphoma patients are one example from the field of cancer therapy. These patients conditions improved so rapidly after they received an innovative lymphoma treatment that they were able to continue working. General access to new, innovative treatment methods is not, as is often falsely asserted, the cause of the sharp increase in healthcare costs. If an expensive treatment reduces costs at a later stage, it can be a good investment when measured over the entire treatment cycle. Price in and of itself is an insufficient basis for assessing the efficiency of a treatment. At the bottom line, an expensive treatment that gets the patient back to work sooner may be more economical than a cheaper therapy with a much longer convalescence period. (Source: Economiesuisse, Towards a New Swiss Healthcare Policy: Guidelines of the Economy, 2011) Direct healthcare costs (CHF 60 billion) Indirect healthcare costs (CHF 74 billion) Direct cost saving: Quicker improvement in condition and recovery & reduced pain and suffering Indirect cost saving: reduced absence from work and caregiving costs Source: Interpharma, Polynomics,

13 Making a mark improving lives Astonishing advances have been made in medicine in the past 50 years, resulting in significant improvements in the options for treating disease. People not only live longer, but also stay healthier as they grow older. Because patients receive better treatment and return to health sooner, they can also get back to work earlier. Particularly in times of economic turbulence, the pharmaceutical industry has a balancing effect on the Swiss economy and national prosperity. I m glad to be part of a company that is committed to medical progress and a better life for patients. Dr Pia Ballschmieter (Strategic Account Manager) Did you know that the pharmaceutical industry is estimated to be contributing around 40% to the increase in life expectancy thanks to innovative medicines (+2.5 years between 1970 and 2001)? (Source: Swiss Economic Institute, ETH Zurich, 2011) Roche is the only company to have introduced seven cancer treatments in Switzerland capable of improving patients' chances of survival? Roche exports in the past three years are equal to Switzerland s total annual healthcare costs (approx. CHF 60 billion)? (Source: Interpharma brochure: "The Swiss Pharmaceutical Market", 2011) 25

14 Roche in Switzerland Key facts in brief A strong commitment to R&D CHF 2 billion in R&D investments 25% of Roche s worldwide R&D expenditure: doing R&D in Switzerland is a high priority for Roche, with daily investment of over CHF 5 million in Basel 3,500 research staff members Roche is one of the three leading research institutions in Switzerland Successful innovation track record 7 approved cancer medicines yielding The only company with 7 cancer improved survival rates medicines that improve patients chance of survival >100 trials conducted with some Many trials are successfully placed in 1,900 patients (since 2000) Switzerland doctors and patients have access to new treatments 8 medicines and indications fast-tracked Reflects Roche s strong innovative for approval in the past 4 years capacity. Fast-track approval is granted to highly innovative medicines in order to give patients faster access to new treatments A dependable driver of the economy (2011) >CHF 500 m in sales CHF 20,000 m in exports 1% of Roche global sales Roche accounts for 11% of total Swiss exports Major employer and educator Approx. 40,000 jobs dependent on Roche, including 10,940 Roche employees Each job at Roche generates more than 2.5 additional indirect jobs in the Swiss economy 380 apprenticeship places One of Switzerland s biggest providers of vocational training Roche takes a clear responsibility for the younger generation 231,880 hours of staff training Roche makes investing in employee training a top priority 26 27

15 Roche Pharma (Switzerland) Ltd 4153 Reinach 01/2013